COMMUNIQUÉS West-GlobeNewswire

T1D Exchange Names New Board Members
11/12/2018
Expanded Board to Strengthen Type 1 Diabetes Expertise and Philanthropic Reach BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- T1D Exchange , a nonprofit, research organization dedicated to accelerating therapies and [...]
Intensity Therapeutics Strengthens Intellectual Property Portfolio with Issuance of Several New Patents in Asia and Australia
11/12/2018
Patents granted in five countries protect the Company’s novel technology and intratumoral, immune cell-activating product candidates, including INT230-6 WESTPORT, Conn., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Intensity [...]
Helius Medical Technologies, Inc. Announces Exercise of Underwriters’ Overallotment Option
11/12/2018
NEWTOWN, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”) announced today that the underwriters of its previously announced public offering of [...]
3rd Quarter Results
11/12/2018
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 and Operational Progress Continued Momentum in [...]
Griffon Pharmaceuticals appoints Dr. Marc Cluzel to Board of Directors
11/12/2018
MONTREAL, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Montreal-based biopharmaceutical company Griffon Pharmaceuticals Inc. (“Griffon”) announced today that Marc Cluzel, MD, PhD, joins the company’s Board of Directors. Dr. Cluzel [...]
Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer
11/12/2018
BUFFALO, N.Y., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today [...]
Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia
11/12/2018
NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]
Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL
11/12/2018
YARDLEY, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company received [...]
CHMP Extends Review Period for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa)
11/12/2018
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]
Transactions in relation to share buyback program
11/12/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Tetra Bio-Pharma Confirms Agreements With Multiple Suppliers
11/12/2018
Quality and volume of Active Pharmaceutical Ingredients (API) ensured ORLEANS, Ontario, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“ Tetra ” or “ TBP ”), (TSX VENTURE: TBP) (OTCQB: TBPMF) a leader in [...]
Santhera's Extraordinary General Meeting Approves Capital Increase
11/12/2018
Pratteln, Switzerland, December 11, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that a vast majority of shareholders approved the ordinary capital increase at today's Extraordinary General Meeting (EGM). [...]
Farmako: Cannabis distributor to become gateway to Europe
11/12/2018
Company is first to apply for a licence in the United Kingdom AAA-Team pushes to become gateway to Europe Company first to apply for distribution licences in UK Support of Canadian LP to obtain EU-GMP Focus on research [...]
A new scientific publication from AroCell confirming the value of AroCell TK 210 ELISA as a tool in drug discovery and development
11/12/2018
A peer-reviewed article has been published in the journal Nucleosides, Nucleotides and Nucleic Acids, entitled “Doxorubicin effects on leukemia and breast cancer cells in culture on the Thymidine Kinase 1 protein levels [...]
Rule 2.9 Announcement
11/12/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 11 December 2018 [...]
Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid
11/12/2018
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid Paris and Boston, December 11 th 2018 - 7 [...]
Néovacs et Centurion Pharma poursuivent leur coopération en lupus suite aux résultats de l'étude de phase IIb avec l'IFNalpha Kinoide
11/12/2018
COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS ET CENTURION PHARMA POURSUIVENT LEUR COOPÉRATION EN LUPUS SUITE AUX RÉSULTATS DE L'ÉTUDE DE PHASE IIB AVEC L'IFNalpha KINOIDE Paris et Boston, [...]
Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA
11/12/2018
Regulated information Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings Gosselies, Belgium, 11 December 2018, 7am CET– BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone [...]
Bone Therapeutics SA : Notification de transparence reçue de la part de S.R.I.W. SA et Sofipôle SA
11/12/2018
Information réglementée Article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes Gosselies, Belgique, le 11 décembre, 7h00 CET - BONE THERAPEUTICS (code Euronext Bruxelles et [...]

Pages